4-(3-methylbutyryl)pyridine | 79251-07-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(3-methylbutyryl)pyridine
• 英文别名: isobutyl pyridin-4-yl ketone；isobutyl 4-pyridyl ketone；3-Methyl-1-(pyridin-4-yl)butan-1-one；3-methyl-1-pyridin-4-ylbutan-1-one
• CAS: 79251-07-3
• 化学式: C₁₀H₁₃NO
• 分子量: 163.219
• InChiKey: OXKATPYKOFUGFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(3-methylbutyryl)pyridine 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 18.0h， 生成 N'-(3-Methyl-1-pyridin-4-yl-butyl)-hydrazinecarboxylic acid tert-butyl ester
  参考文献：
  名称：

  Synthesis of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5- b ]quinoline-1,4,10(5 H )-triones as NMDA glycine-site antagonists

  摘要：

  Several members of the 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones (2) have been identified as being potent and selective NMDA glycine-site antagonists. Increasing size of the alkyl substituent on the alpha-carbon led to a progressive decrease in binding affinity. Some of these analogues possess improved drug-like properties such as cellular permeability, solubility and oral absorption. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00750-9

文献信息

• ARYL DIHYDROPYRIDINONE AND PIPERIDINONE MGAT2 INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20130143843A1

  公开（公告）日：2013-06-06

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

  本发明提供了以下式（I）的化合物： 或其立体异构体，或其药学上可接受的盐，其中所有变量如本文所定义。这些化合物是单酰基甘油酰基转移酶2（MGAT2）抑制剂，可用作药物。
• Nonsteroidal cardiotonics. 3. New 4,5-dihydro-6-(1H-indol-5-yl)pyridazin-3(2H)-ones and related compounds with positive inotropic activities
  作者：Alfred Mertens、Walter Gunar Friebe、Bernd Mueller-Beckmann、Wolfgang Kampe、Lothar Kling、Wolfgang Von der Saal

  DOI：10.1021/jm00172a031

  日期：1990.10

  substituted indolyldihydropyridazinones and related compounds 1-18 were synthesized and evaluated for positive inotropic activity. In rats, most of these indole derivatives produced a dose-related increase in myocardial contractility with little effect on heart rate and blood pressure. Compound 13, 4,5-dihydro-5-methyl-6-(2-pyridin-4-yl-1H-indol-5-yl)pyrazin-3(2H) -one (BM 50.0430), was further investigated

  合成了一系列取代的吲哚基二氢吡啶并酮和相关化合物1-18，并评价了其正性肌力活性。在大鼠中，大多数这些吲哚衍生物会引起剂量相关的心肌收缩力增加，而对心率和血压影响很小。在猫中进一步研究了化合物13，4,5-二氢-5-甲基-6-（2-吡啶-4-基-1H-吲哚-5-基）吡嗪-3（2H）-1（BM 50.0430） 。该动物模型中收缩力的增加不是通过刺激β-肾上腺素受体介导的。对有意识的狗口服1 mg / kg的化合物后，化合物13和匹莫苯丹在6.5小时后仍然有效。然而，在这段时间之后，13的强心作用至少是匹莫苯丹的2倍。
• Anthelmintic pyridinyl acylhydrazones derivatives
  申请人：Upjohn Company

  公开号：US05011932A1

  公开（公告）日：1991-04-30

  This invention concerns a process for killing internal parasites, especially nematodes and cestodes affecting warm blooded animals such as sheep, cattle, swine, goats, dogs, cats, horses and humans as well as poultry by administering an effective amount of a compound of the Formula I: ##STR1## Certain of the compounds of Formula I are novel and in further embodiments of the invention provide novel compounds and compositions for use in the process of the invention. The compounds are readily prepared by conventional chemical reactions. Various pyridinyl acylhydrazones of Formula I demonstrate broad-spectrum anthelmintic activity in sheep upon oral and/or parenteral administration.

  这项发明涉及一种用于杀灭内部寄生虫的过程，特别是影响温血动物（如羊、牛、猪、山羊、狗、猫、马和人类以及家禽）的线虫和绦虫，通过给予化合物I的有效量来实现：##STR1## 公式I的某些化合物是新颖的，并在该发明的进一步实施中提供了用于该发明过程的新型化合物和组合物。这些化合物可通过常规化学反应轻松制备。公式I的各种吡啶基酰肼酮在羊体内经口和/或皮下给药显示出广谱驱虫活性。
• Anthelmintic pyridinyl acylhydrazones
  申请人：The Upjohn Company

  公开号：US05023334A1

  公开（公告）日：1991-06-11

  This invention concerns a process for killing internal parasites, especially nematodes and cestodes affecting warm blooded animals such as sheep, cattle, swine, goats, dogs, cats, horses and humans as well as poultry by administering an effective amount of a compound of the Formula I: ##STR1## Certain of the compounds of Formula I are novel and in further embodiments of the invention provide novel compounds and compositions for use in the process of the invention. The compounds are readily prepared by conventional chemical reactions. Various pyridinyl acylhydrazones of Formula I demonstrate broad-spectrum anthelmintic activity in sheep upon oral and/or parenteral administration.

  本发明涉及一种杀死内寄生虫的过程，特别是影响温血动物如绵羊、牛、猪、山羊、狗、猫、马和人类以及家禽的线虫和绦虫，通过给予化合物I式的有效量进行治疗。式I的某些化合物是新颖的，在本发明的进一步实施中提供了用于该过程的新颖化合物和组合物。这些化合物可以通过常规化学反应轻松制备。式I的各种吡啶酰肼类化合物在口服和/或静脉注射后对绵羊表现出广谱驱虫活性。
• QUINOLINE COMPOUNDS AND METHODS OF USE
  申请人：Gaudino John

  公开号：US20110053931A1

  公开（公告）日：2011-03-03

  Compounds of Formula (I), and stereoisomers, geometric isomers, tautomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof, are useful for inhibiting receptor tyrosine kinases and for treating hyperproliferative disorders mediated thereby. Methods of using compounds of Formula (I), and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  式（I）的化合物及其立体异构体、几何异构体、互变异构体、溶剂化物、代谢物、盐和药学上可接受的前药，用于抑制受体酪氨酸激酶并治疗由此介导的过度增殖性疾病。本文揭示了使用式（I）的化合物及其立体异构体、几何异构体、互变异构体、溶剂化物和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。